http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Chaudhuri, Suhnrita,Acharya, Sagar,Chatterjee, Sirshendu,Kumar, Pankaj,Singh, Manoj Kumar,Bhattacharya, Debanjan,Basu, Anjan Kumar,Dasgupta, Shyamal,Flora, S.J.S.,Chaudhuri, Swapna Asian Pacific Journal of Cancer Prevention 2012 Asian Pacific journal of cancer prevention Vol.13 No.6
Arsenic exposure is a serious health hazard worldwide. We have previously established that it may result in immune suppression by upregulating Th2 cytokines while downregulating Th1 cytokines and causing lymphocytic death. Treatment modalities for arsenic poisoning have mainly been restricted to the use of chelating agents in the past. Only recently have combination therapies using a chelating agent in conjunction with other compounds such as anti-oxidants, micronutrients and various plant products, been introduced. In the present study, we used T11TS, a novel immune potentiating glycopeptide alone and in combination with the sulfhydryl-containing chelator, mono-iso-amyl-dimarcaptosuccinic acid (MiADMSA) as a therapeutic regimen to combat arsenic toxicity in a mouse model. Results indicated that Th1 cytokines such as TNF-${\alpha}$, $IFN{\gamma}$, IL12 and the Th2 cytokines such as IL4, IL6, IL10 which were respectively downregulated and upregulated following arsenic induction were more efficiently restored to their near normal levels by T11TS alone in comparison with the combined regimen. Similar results were obtained with the apoptotic proteins studied, FasL, BAX, BCL2 and the caspases 3, 8 and 9, where again T11TS proved more potent than in combination with MiADMSA in preventing lymphocyte death. The results thus indicate that T11TS alone is more efficient in immune re-establishment after arsenic exposureas compared to combination therapy with T11TS+MiADMSA.
Interplay of Vitamin D and CYP3A4 Polymorphisms in Endocrine Disorders and Cancer
Siva Swapna Kasarla,Vannuruswamy Garikapati,Yashwant Kumar,Sujatha Dodoala 대한내분비학회 2022 Endocrinology and metabolism Vol.37 No.3
Vitamin D has received considerable optimistic attention as a potentially important factor in many pathological states over the past fewdecades. However, the proportion of the active form of vitamin D metabolites responsible for biological activity is highly questionablein disease states due to flexible alterations in the enzymes responsible for their metabolism. For instance, CYP3A4 plays a crucial rolein the biotransformation of vitamin D and other drug substances. Food-drug and/or drug-drug interactions, the disease state, geneticpolymorphism, age, sex, diet, and environmental factors all influence CYP3A4 activity. Genetic polymorphisms in CYP450-encodinggenes have received considerable attention in the past few decades due to their extensive impact on the pharmacokinetic and dynamicproperties of drugs and endogenous substances. In this review, we focused on CYP3A4 polymorphisms and their interplay with vitamin D metabolism and summarized the role of vitamin D in calcium homeostasis, bone diseases, diabetes, cancer, other diseases, anddrug substances. We also reviewed clinical observations pertaining to CYP3A4 polymorphisms among the aforementioned diseaseconditions. In addition, we highlighted the future perspectives of studying the pharmacogenetics of CYP3A4, which may have potential clinical significance for developing novel diagnostic genetic markers that will ascertain disease risk and progression.
Design, Synthesis and Biological Evaluation of Novel Analogs of Bortezomib
Rao, R. Janaki Rama,Rao, A.K.S. Bhujanga,Swapna, K.,Rani, B. Baby,Kumar, S. Prasanna,Awantika, S.,Murthy, Y.L.N. Korean Chemical Society 2011 대한화학회지 Vol.55 No.5
Novel analogs of bortezomib were designed, synthesized and in vitro biological evaluation was carried out using human tumor cell lines A549 and PC3. Docking studies of these analogs of bortezomib was discussed. According to biological investigations, the inhibitors 4, 6, and 8 were found to be more potent than reference drug candidate bortezomib. A549 cell line showed significant sensitivity towards 4, 6, and 8 with $IC_{50}$ values 14.03, 18.5, and 12.4 nM, respectively, and PC3 cell line showed IC50 values 26.1, 37.0, and 21.2 nM, respectively. The $IC_{50}$ values of bortezomib in these cell lines are 27.3 nM and 42.0 nM.